In Vitro Study Of EGFR Monoclonal Antibody Conjugate Tubulin Inhibitoson Inhibition Of Human Lung Cancer

Objective:This experiment aims to study the inhibitory effect and the role in the cell cycle of epidermal growth factor receptor(EGFR) monoclonal antibody conjugate tubulin inhibitor(ADC) on human lung cancer A549 cells in vitro. Methods:1、Cell growth inhibition rate: To detect the inhibitory effect of the epidermal growth factor receptor(EGFR) monoclonal antibody conjugate tubulin inhibitor(ADC), cetuximab and cisplatin in different concentration and thedifferent time on human lung cancer A549 cells.2、the cell cycle detection: A549 cells are respectively treated with epidermal growth factor receptor(EGFR) monoclonal antibody conjugate tubulin inhibitor(ADC),or cetuximab, or cisplatin in different concentrations.After 24 hours, detect the cell cycle phase by flow cytometry detection. Results:1、the cell growth inhibition rate results: ADC group has obvious inhibitory effect on the A549 cells in all concentrations, cetuximab group has partly inhibitory effect on A549 cell. after 24 hours, the cell inhibition rate increased with the increase of the concentration under the effect of ADC and cetuximab, P < 0.05, has statistical significance. after 48 hours,the cell inhibition rate increased accom-panywith the concentration in low and medium concentration, P < 0.05. in high concentration the inhibitory effect does not increase accompany with concentration and time, P > 0.05.when ADC molarity is one percent of Cisplatin, in 24 hours,P > 0.05. in 48 hours, P < 0.05, ADC has more effect inhibitory than Cisplatin.ADC, cetuximab and cisplatin on A549 cells compared with the control,the inhibition rate increased accompany with concentration and effect time in the limit concentration. the effect of ADC is better than cetuximab.ADC is better than cisplatin under the same molarity.2、the cell cycle results: G2 / M phase were significantly increased, the G1 and S phase cell is less than the control group under the effect of ADC in different concentration compared with the control, P < 0.01, significant differences, suggesting the retardation of the ADC in G2 / M phase.Cetuximab with different concentration is given priority to with G1 phase cells, G1, S, G2 had no obvious difference compared with control gourps, P > 0.05.Cisplatin group compared with control groups with different concentration cell periods, G1 phase cells increased obviously, S, G2 cells decreased, P < 0.05, there is statistical significance, suggesting the retardation of G1 phase.The comparison of same drug in different concentrations between each phase of the cell P > 0.05, suggesting the retardation of cell cycle is irrelevant with concentration. Compare with ADC and cetuximab with the same molar concentration 0.0134mmol/L(molecular weight is close) in different periods, P < 0.01, suggesting the retardation cycle of ADC and cetuximab is different.Compare ADC with 0.0134mmol/L and cisplatin 1.33mmol/L(ADC molarity about 0.01 of cisplatin), P < 0.01 is significantly different, suggesting that ADC and cisplatin block cycle is different. Conclusion:The epidermal growth factor receptor(EGFR) monoclonal antibody conjugate tubulin has obvious inhibitory effect on human lung cancer A549 cells in vitro,the effect is better than cetuximab and cisplatin.The(EGFR) monoclonal antibody conjugate tubulin is in G2 / M phase retardation, the retardation cell cycle is different from that of cetuximab and cisplatin.